Company Overview - Dazhonglin Pharmaceutical Group Co., Ltd. is located in Guangzhou, Guangdong Province, and was established on February 12, 1999. It was listed on July 31, 2017. The company primarily engages in the retail of traditional Chinese and Western medicines, health products, medical devices, and other goods [2]. Financial Performance - For the first half of 2025, Dazhonglin achieved operating revenue of 13.523 billion yuan, representing a year-on-year growth of 1.33%. The net profit attributable to shareholders was 798 million yuan, reflecting a year-on-year increase of 21.38% [2]. - Since its A-share listing, Dazhonglin has distributed a total of 3.355 billion yuan in dividends, with 1.624 billion yuan distributed over the past three years [3]. Stock Performance - As of September 2, Dazhonglin's stock price increased by 2.01%, reaching 17.27 yuan per share, with a trading volume of 156 million yuan and a turnover rate of 0.80%. The total market capitalization is 19.668 billion yuan [1]. - Year-to-date, Dazhonglin's stock price has risen by 17.08%. In the last five trading days, it increased by 0.70%, while it decreased by 2.98% over the past 20 days and increased by 4.73% over the last 60 days [2]. Shareholder Information - As of June 30, 2025, Dazhonglin had 31,500 shareholders, a decrease of 10.07% from the previous period. The average number of circulating shares per shareholder increased by 11.20% to 36,097 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 90.448 million shares, an increase of 12.4318 million shares compared to the previous period [3]. Capital Flow - On September 2, the net outflow of main funds was 6.7582 million yuan, with large orders accounting for 12.78% of purchases and 16.27% of sales [1].

Group 1 - The core point of the article is the issuance of convertible bonds by Dashenlin Pharmaceutical Group Co., Ltd., which aims to raise a total of RMB 1,405 million, with the net amount after expenses being RMB 1,389.48 million [1][21] - The bonds have a face value of RMB 100 each and a term of 6 years, from October 22, 2020, to October 21, 2026 [2][4] - The coupon rates for the bonds are structured to increase over the years, starting at 0.30% in the first year and reaching 2.00% in the sixth year [2][3] Group 2 - The company has a robust retail network with 10,503 direct stores across 21 provinces, focusing on providing quality health products and services [18][19] - In 2024, the company reported a revenue of RMB 2,649.65 million, an increase of 8.01% compared to 2023, while the net profit attributable to shareholders decreased by 21.58% to RMB 914.76 million [20] - The company maintains a strong supply chain and logistics system, with over 10,000 long-term partnerships with manufacturers, ensuring efficient product delivery [17][18] Group 3 - The company has established a comprehensive management system for the use of raised funds, ensuring they are stored in a dedicated account and used according to regulatory requirements [13][21] - The credit rating for the bonds is AA, indicating a stable outlook, as assessed by Zhongjian Pengyuan Credit Rating Co., Ltd. [14][15] - The company has a clear strategy for expanding its market presence through both direct and franchise models, enhancing its competitive edge in the pharmaceutical retail sector [19][20]